• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

    5/18/23 8:00:00 AM ET
    $ALLO
    $AMGN
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email

    Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

    • Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipeline
    • Former Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert
    • Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy

    San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the appointment of Arun Balakumaran, M.D., Ph.D., as Chief Medical Officer (CMO), effective 22 May.

    An expert in immuno-oncology and cell and gene therapy, Dr. Balakumaran brings more than 15 years of clinical development experience at leading biotechnology and pharmaceutical companies, including Merck and Amgen, to the Company. At Replay, Dr. Balakumaran will support the clinical development of Replay's differentiated portfolio of next-generation genomic medicines and technology platforms, including its first-in-class engineered TCR-NK cell therapy programs that are anticipated to enter the clinic later this year.

    Dr. Balakumaran joins Replay from Allogene Therapeutics (NASDAQ:ALLO), where he served as CMO and Senior Vice president, overseeing the Company's clinical development strategy across multiple allogeneic cell therapy programs. Prior to that, he held roles of increasing seniority at Merck (NASDAQ:MRK), where he was the Product Development Lead for Hematological Malignancies and led the activities resulting in breakthrough designations and the eventual approval of Pembrolizumab® in lymphoma. Prior to that he was Clinical Research Medical Director at Amgen (NASDAQ:AMGN), and Medical Lead in Oncology.

    Dr. Balakumaran began his career at the National Institutes of Health (NIH), where he was Medical Lead for the Bone Marrow Stromal Cells (MSC) Transplant Center. He is a board-certified hematologist and medical oncologist and holds a Master's degree in healthcare management from Harvard University. Dr. Balakumaran also serves on the Board of Onco Filtration Inc. and the Scientific Advisory Board of SDS Optic.

    Dr. Balakumaran will, additionally, join Replay's engineered TCR-NK cell therapy product company Syena as CMO, where he will support the clinical development of its first-in-class and first-in-human engineered TCR-NK cell therapy clinical programs in both hematological malignancies and solid tumors. Syena was co-founded by Professor Katy Rezvani, M.D., Ph.D., and is developing a scalable, off-the-shelf, cord blood-derived engineered TCR-NK platform, which was licensed exclusively from The University of Texas MD Anderson Cancer Center, in February 2023.

    Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay, commented: "Arun's extensive expertise across cell and gene therapy, and immuno-oncology, will be invaluable for Replay and its product companies, including our first-in-class engineered TCR-NK cell therapy company, Syena. He will be joining a rapidly expanding team of world-class industry experts, academics, and entrepreneurs at Replay, where we are focused on delivering new therapeutic options for some of the key global medical challenges addressable using genomic medicine and engineered cell therapies. We are delighted to welcome him into our team."

    Lachlan MacKinnon, CEO and Co-Founder of Replay, added, "We have watched Arun's progress at Allogene Therapeutics where he has been instrumental in advancing their allogeneic cell therapy programs into the clinic. His knowledge and experience will be of critical importance to the Company as we progress our genomic medicine pipeline, including the first-in-class TCR-NKs that we are developing within our engineered TCR-NK cell therapy product company, Syena."

    "Replay has the potential to transform the future of genomic medicine through its suite of genomic medicine platform technologies, engineered cell therapies, and innovative approach to corporate structure and product development," said Dr. Arun Balakumaran, Chief Medical Officer of Replay. "The engineered TCR-NK platform that is being developed in Syena in particular, provides the promise of a highly scalable and off-the-shelf cell therapy with the potential to evade the primary mechanism of acquired resistance in existing cell therapies, through their innate anti-tumor activity. I look forward to working with the Replay executive team, Katy Rezvani at MD Anderson, and the Syena team to progress engineered TCR-NKs and the Company's other programs and technologies including HSV-based gene therapy, into the clinic for the benefit of patients with high unmet medical needs."

    Ends

    About Replay

    Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies – including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform – to address the scientific challenges currently limiting clinical progress and preventing genomic medicine from realizing its full potential. The Company's hub-and-spoke business model separates technology development within Replay from therapeutic development in product companies that leverage its technology platforms. For example, the Company recently incorporated a first-in-class engineered TCR-NK cell therapy product company developed by Professor Katy Rezvani at the MD Anderson Cancer Center. Replay's synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay's four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. Replay is led by a world-class team of academics, entrepreneurs, and industry experts.

    The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.

    Replay is headquartered in San Diego, California, and London, UK. For further information please visit www.replay.bio and follow us on LinkedIn and Twitter. 

    Contacts:

    Replay

    Dr Adrian Woolfson / Lachlan MacKinnon

    [email protected]

    Consilium Strategic Communications – Media relations

    Amber Fennell / David Daley / Melissa Gardiner

    [email protected]



    Primary Logo

    Get the next $ALLO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLO
    $AMGN
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    9/17/2025$90.00Buy → Hold
    Berenberg
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Allogene Therapeutics Inc.
    $ALLO
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Allogene Therapeutics Inc.
    $ALLO
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    More analyst ratings

    $ALLO
    $AMGN
    $MRK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    SEC Filings

    View All

    Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    9/9/25 4:33:09 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amgen Inc.

    SCHEDULE 13G/A - AMGEN INC (0000318154) (Subject)

    9/8/25 11:06:01 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Merck & Company Inc.

    424B5 - Merck & Co., Inc. (0000310158) (Filer)

    9/4/25 4:15:44 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLO
    $AMGN
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial

    Results showed the benefits of early initiation of WINREVAIR within the first year after PAH diagnosis HYPERION results were presented today at ERS 2025 and simultaneously published in the New England Journal of Medicine Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worsening even

    9/30/25 3:39:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

    THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs.  "This expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain," said Robert A. Bradway, chairman and chief executive officer a

    9/26/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & CCO Grygiel Nancy A. sold $376,280 worth of shares (1,267 units at $296.99), decreasing direct ownership by 15% to 7,209 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    8/22/25 7:21:55 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ishrak Omar was granted 121 shares, increasing direct ownership by 2% to 6,242 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    8/12/25 7:27:28 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Holley Charles M was granted 147 shares, increasing direct ownership by 1% to 11,470 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    8/12/25 7:25:42 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

    4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

    5/20/24 9:33:32 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Merck downgraded by Berenberg with a new price target

    Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00

    9/17/25 7:56:07 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Amgen

    Raymond James resumed coverage of Amgen with a rating of Mkt Perform

    9/3/25 8:26:50 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim resumed coverage on Amgen with a new price target

    Guggenheim resumed coverage of Amgen with a rating of Neutral and set a new price target of $288.00

    5/20/25 8:11:08 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $ALLO
    $AMGN
    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

    10/1/25 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS

    THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs.  "This expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain," said Robert A. Bradway, chairman and chief executive officer a

    9/26/25 9:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

    THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analys

    9/9/25 12:12:26 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLO
    $AMGN
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

    SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

    11/12/24 1:26:25 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Allogene Therapeutics Inc.

    SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

    11/4/24 10:57:36 AM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

    SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)

    2/14/24 4:36:10 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care